OOIR: Observatory of International Research

Papers

(The H4-Index of Gut is 75. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Direct toll-like receptor triggering in colorectal cancer-associated stromal cells elicits immunostimulatory properties leading to enhanced immune cell recruitment	1101
Porcine-derived pancreatic enzyme replacement therapy: a cause of hepatitis E virus transmission?	732
Liquid biopsy to identify Barrett’s oesophagus, dysplasia and oesophageal adenocarcinoma: theEMERALDmulticentre study	632
GI highlights from the literature	361
Genetic variation inTERTmodifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study	314
GI highlights from the literature	267
Defining the key intrahepatic gene networks in HCV infection driven by sex	265
Targeted intervention to achieve waste reduction in gastrointestinal endoscopy	257
Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea	223
Automated sizing of colorectal polyps using computer vision	213
Consensus-based development of a causal attribution system for post-ERCP adverse events	208
Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance	196
Climate change: a survey of global gastroenterology society leadership	189
Gastric variceal bleeding in a patient with alcohol abuse: business as usual?	178
Liver injury, hypoalbuminaemia and severe SARS-CoV-2 infection	172
Picking up microbial clues in early-onset colorectal cancer	165
GI highlights from the literature	164
Proton pump inhibitors and gastric cancer: a population-based cohort study	151
Transmural intestinal fibrosis in men and mice	148
NGS mismapping confounds the clinical interpretation of the PRSS1 p.Ala16Val (c.47C>T) variant in chronic pancreatitis	147
Stool microRNA profiling— dumpster diving for a master marker?	147
Genetically proxied ketohexokinase function and risk of colorectal cancer: a Mendelian randomisation study	146
DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma	141
Omics studies in gastroenterological and hepatological patient populations: current impact and future promise exemplified by a large study of HCV-infected livers	139
End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma	138

Impact of delayed screening invitations on screen-detected and interval cancers in the Dutch colorectal cancer screening programme: individual-level data analysis	137
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis	135
Towards a new era with safer µ-opiate receptor analgesia	135
Current therapies and new developments in NASH	133
CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival	129
Innumerable nodules in all parts of the small intestine	128
Right tool for the right bleeder	128
Genetic analyses of treatment response in primary care IBS, a pilot study	127
Clinical advances: pregnancy in gastroenterologic and hepatic conditions	126
Reply to: “Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data”	121
Inflammation-associated gut microbiome in postacute sequelae of SARS-CoV-2 points towards new therapeutic targets	117
Letter to the editor regarding: Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study)	117
Ferritin—a promising biomarker in MASLD	115
Evaluating microbial determinants of donor efficacy to translate faecal microbiota transplantation from research to clinical practice	114
Diagnostic dilemma: sudden onset of multiple skin lesions in a patient with intestinal disease	114
Growth rates and histopathological outcomes of small (6–9 mm) colorectal polyps based on CT colonography surveillance and endoscopic removal	114
Large volume paracentesis: to do or where to do?	111
Novel mouse model for studying transmural intestinal fibrosis and creeping fat formation in stricturing Crohn’s disease	109
Blood and guts	108
Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn’s disease highlight earliest events of pathogenesis	108
Empiric use of standard triple therapy inHelicobacter pylorieradication does not require readjustment in the clarithromycin resistance cut-off point	107
Hidden link in gut–joint axis: gut microbes promote rheumatoid arthritis at early stage by enhancing ascorbate degradation	106
The fundamentals: understanding the climate change crisis	104
Immunoglobulin A–specific deficiency induces spontaneous inflammation specifically in the ileum	103
Scoring systems for diverticular disease	102
More than meets the eye: a strange cause of bowel obstruction and perforation	101
Multiple inflammatory mechanisms in eosinophilic oesophagitis make it unlikely that single pathway inhibition by monoclonal biological therapies would succeed	100
Joint Asian Pacific Association of Gastroenterology (APAGE)–Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines on the use of non-invasive biomarkers for diagnosis of col	98
MAFLD, HCC and the dilemma of (changing) terminology in liver diseases	95
Patient-reported experience of colonoscopy in Italy: a multicentre prospective observational study	93
Plasma extracellular vesicles contain unannotated small RNA clusters suitable as biomarkers for detecting early hepatocellular carcinoma	92
New AI model for neoplasia detection and characterisation in inflammatory bowel disease	92
Advancing with cancer immunotherapeutics: CD29⁺regulatory T cell antagonism	90
CT colonography remains an important test for colorectal cancer	89
Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease	88
Relative risk rather than absolute risk reduction should be preferred to sensitise the public to preventive actions	85
Clinical outcome of non-curative endoscopic submucosal dissection for early colorectal cancer	85
Artificial intelligence in EUS for autoimmune pancreatitis: bias and real life	84
Escape from cell-cell and cell-matrix adhesion dependence underscores disease progression in gastric cancer organoid models	82
Over-the-scope clips versus standard treatment	82
Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?	80
COVID-19 transmission following outpatient endoscopy during pandemic acceleration phase involving SARS-CoV-2 VOC 202012/01 variant in UK	80
Faecalibacterium prausnitzii: one species with multiple potential implications in cancer research	79
FTO/m6A/GPNMB axis: a novel promising target for hepatocellular carcinoma (HCC) treatment?	78
Impact of margin thermal ablation after endoscopic mucosal resection of large (≥20 mm) non-pedunculated colonic polyps on long-term recurrence	78
Genetic and transcriptomic landscape of colonic diverticulosis	77
Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis	77
A mucus production programme promotes classical pancreatic ductal adenocarcinoma	76
Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women	76
Autoimmune gastritis may be less susceptible to cancer development thanHelicobacter pylori-related gastritis based on histological analysis	76